Illumina, Inc. $ILMN Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 832,690 shares of the life sciences company’s stock after purchasing an additional 124,246 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.54% of Illumina worth $79,081,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Loomis Sayles & Co. L P lifted its position in shares of Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after buying an additional 78,317 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after buying an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC raised its stake in Illumina by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after acquiring an additional 21,342 shares in the last quarter. Bank of America Corp DE raised its stake in Illumina by 1.9% during the 2nd quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock worth $184,222,000 after acquiring an additional 35,167 shares in the last quarter. Finally, Edmond DE Rothschild Holding S.A. lifted its position in Illumina by 140.1% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock valued at $136,312,000 after acquiring an additional 833,750 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the topic of several research reports. JPMorgan Chase & Co. dropped their price objective on Illumina from $130.00 to $120.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 31st. Guggenheim lifted their price target on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Robert W. Baird set a $137.00 price objective on Illumina in a research note on Friday, February 6th. Finally, Wall Street Zen raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $127.94.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $120.54 on Tuesday. The stock has a fifty day moving average price of $135.52 and a 200 day moving average price of $117.54. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The company has a market cap of $18.43 billion, a PE ratio of 22.12, a P/E/G ratio of 2.25 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the previous year, the company posted $0.95 EPS. Illumina’s revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Insider Activity

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider owned 17,887 shares in the company, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.